Glenmark Pharma has rolled out an EMI scheme for cancer patients in order to help them continue the treatment and meet the high cost of medication. The company has included its two drugs - Abirapro prescribed for prostate cancer and Evermil, indicated for different cancers, such as breast and renal cell carcinoma - under the scheme.
Currently, Abirapro 250 mg in 120-pack size is priced at Rs 39,990. The drug in a 60-pack size costs Rs 19,995 and 30-pack size at Rs 9,998, while the company’s 10-tablet pack of 10 mg Evermil tablets is priced at Rs. 29,965 while the 5 mg tablets in 10 tablet pack is priced at Rs. 19,900.
Moreover, the company is planning to introduce a flexi payment scheme for other high-value cancer drugs very soon. Both Abirapro and Evermil need to be taken for long durations of time ranging from a few months to over a year or more. Both the drugs are critical for the survival of patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: